Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Crinetics Pharmaceuticals, Inc. (CRNX : NSDQ)

• Company Description    CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO. Number of Employees: 437

• Price / Volume Information    Yesterday's Closing Price: $34.00 Daily Weekly Monthly 20 Day Moving Average: 1,067,223 shares Shares Outstanding: 94.18 (millions) Market Capitalization: $3,201.98 (millions) Beta: 0.28 52 Week High: $62.53 52 Week Low: $24.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.52% 12.50% 12 Week 11.48% 1.26% Year To Date -33.50% -41.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6055 Lusk Boulevard - San Diego,CA 92121 USA ph: 858-450-6464 fax: - ir@crinetics.com http://www.crinetics.com

• General Corporate Information    Officers R. Scott Struthers - President and Chief Executive Officer Wendell Wierenga - Chairman Marc J.S. Wilson - Chief Financial Officer Camille Bedrosian - Director Caren Deardorf - Director Peer Information Crinetics Pharmaceuticals, Inc. (GSAC) Crinetics Pharmaceuticals, Inc. (CASI) Crinetics Pharmaceuticals, Inc. (ALCD.) Crinetics Pharmaceuticals, Inc. (OMNN) Crinetics Pharmaceuticals, Inc. (CGPI.) Crinetics Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 22663K107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 94.18 Most Recent Split Date: (:1) Beta: 0.28 Market Capitalization: $3,201.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.73 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -30.85% vs. Previous Quarter: -18.27% Sales Growth vs. Year Ago Period: 158.40% vs. Previous Quarter: 185.60% ROE 06/30/25 - -32.28 03/31/25 - -30.95 12/31/24 - -30.90 ROA 06/30/25 - -29.45 03/31/25 - -28.12 12/31/24 - -27.85 Current Ratio 06/30/25 - 17.80 03/31/25 - 22.53 12/31/24 - 23.05 Quick Ratio 06/30/25 - 17.80 03/31/25 - 22.53 12/31/24 - 23.04 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -26,568.53 03/31/25 - -43,191.05 12/31/24 - -28,675.46 Book Value 06/30/25 - 12.44 03/31/25 - 13.39 12/31/24 - 14.29 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©